HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the
“Company”), a novel medical therapy company bringing to market its
proprietary CellFX™ System, announced today that the Compensation
Committee of the Company’s Board of Directors granted non-qualified
stock options covering an aggregate of 37,250 shares of Pulse
Biosciences common stock to eight new non-executive employees under the
Pulse Biosciences 2017 Inducement Equity Incentive Plan on February 15,
The 2017 Inducement Equity Incentive Plan is used exclusively to grant
equity awards to individuals who were not previously an employee or
non-employee director of Pulse Biosciences as an inducement material to
such individual’s entering into employment with Pulse Biosciences in
accordance with Nasdaq Marketplace Rule 5635(c)(4).
The options have an exercise price of $18.09 per share, which is equal
to the closing price of Pulse Biosciences common stock on February 15,
2019. The 37,250 shares underlying the option grants will vest and
become exercisable as to 25% of the shares annually beginning on the
first anniversary of the recipient’s start date, subject to the
recipient’s continued employment with Pulse Biosciences on these vesting
dates. The options are subject to the terms and conditions of the 2017
Inducement Equity Incentive Plan and the award agreements entered into
with each recipient.
About Pulse Biosciences
Pulse Biosciences is a novel medical therapy company bringing to market
its proprietary CellFX™ System utilizing the Company’s proprietary
Nano-Pulse Stimulation™ (NPS™) platform technology. The Company’s CellFX
System provides a novel, precise, non-thermal cellular treatment
technology delivering nanosecond duration energy pulses that impact
cells in treated tissue while sparing surrounding non-cellular tissue.
This unique mechanism of action disrupts the functions of internal cell
structures while maintaining the outer cell membrane, initiating a
cascade of events within the cell resulting in regulated cell death. The
novel characteristics of the Company’s CellFX System mechanism of action
has the potential to significantly benefit patients across multiple
medical applications, including dermatology, the Company’s first planned
commercial application. Beyond dermatology applications, NPS has
demonstrated an ability to induce immunogenic cell death in several
cancer cell lines in pre-clinical studies. The Company believes its NPS
platform technology may play a future role in immuno-oncology as a focal
tumor treatment that can initiate an adaptive immune response. More
information can be found at www.pulsebiosciences.com.
Caution: Pulse Biosciences’ CellFX system and Nano-Pulse Stimulation
(NPS) are for investigational use.
Pulse Biosciences, Inc.
Vice President and Chief Financial Officer
Gitanjali Jain Ogawa, 646-378-2949
Nadine D. Tosk, 504-453-8344